JP2002515031A - タンパク質グリコシル化の阻害および血管疾患の予防 - Google Patents
タンパク質グリコシル化の阻害および血管疾患の予防Info
- Publication number
- JP2002515031A JP2002515031A JP52959097A JP52959097A JP2002515031A JP 2002515031 A JP2002515031 A JP 2002515031A JP 52959097 A JP52959097 A JP 52959097A JP 52959097 A JP52959097 A JP 52959097A JP 2002515031 A JP2002515031 A JP 2002515031A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- albumin
- ldl
- composition
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Feed For Specific Animals (AREA)
- Steroid Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Testing Of Short-Circuits, Discontinuities, Leakage, Or Incorrect Line Connections (AREA)
- Polyesters Or Polycarbonates (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ジクロロフェニルアミノベンゼン酢酸、メチルトルイル−ピロール酢酸、ヒ ドロキシメチル−ピリジルカルバモイル−ベンゾチアジンジオキシド、ジクロロ メチルフェニルアミノ安息香酸、メチル−メチルプロピルベンゼン酢酸、クロロ ベンゾイルメトキシ−メチルインドール酢酸およびフルオロメチル−メチルスル フィニル−フェニルメチレン−インデン酢酸の群から選択された抗−非酵素的グ リコシル化アルブミン化合物の、糖尿病性血管疾患、糖尿病性神経疾患、糖尿病 性腎臓疾患および同様の疾患の予防および治療用医薬の製造のための用途。 2.医薬がアルブミン分子におけるアマドリグルコース付加物の形成を阻害する 請求項1の方法。 3.アルブミンのアマドリグルコース付加物修飾がリジン195、リジン199 、リジン281、リジン439およびリジン525からなる群から選択される1 つ以上の残基において生じる請求項2の方法。 4.医薬が、生物学的に活性である糖結合アルブミンエピトープであってそれら の細胞関連受容体に結合するエピトープの形成を阻害する請求項1の方法。 5.ジクロロフェニルアミノベンゼン酢酸、メチルトルイル−ピロール酢酸、ヒ ドロキシメチル−ピリジルカルバモイル−ベンゾチアジンジオキシド、ジクロロ メチルフェニルアミノ安息香酸、メチル−メチルプロピルベンゼン酢酸、クロロ ベンゾイルメトキシ−メチルインドール酢酸およびフルオロメチル−メチルスル フィニル−フェニルメチレン−インデン酢酸の群から選択された抗−非酵素的グ リコシル化アポB/LDL化合物の、アテローム硬化性心臓血管疾患の予防およ び治療用医薬の製造のための用途。 6.ジクロロフェニルアミノベンゼン酢酸、メチルトルイル−ピロール酢酸、ヒ ドロキシメチル−ピリジルカルバモイル−ベンゾチアジンジオキシド、ジクロロ メチルフェニルアミノ安息香酸、メチル−メチルプロピルベンゼン酢酸、クロロ ベンゾイルメトキシ−メチルインドール酢酸およびフルオロメチル−メチルスル フィニル−フェニルメチレン−インデン酢酸の群から選択された抗−非酵素的グ リコシル化アポB/LDL化合物の、高コレステロール血症の予防および治療用 医薬の製造のための用途。 7.医薬がアポB/LDL分子におけるアマドリグルコース付加物の形成を阻害 する請求項5の方法。 8.医薬がアポB/LDL分子におけるアマドリグルコース付加物の形成を阻害 する請求項6の方法。 9.グリコシル化アルブミンによって生じる糖尿病性血管疾患を予防するための 組成物であって、アルブミンの非酵素的グリコシル化に対して保護する治療上の 分子および治療上許容し得るキャリアーを含む組成物。 10.治療上の分子が、糖尿病性血管疾患、糖尿病性神経疾患、糖尿病性腎臓疾 患および同様の疾患の予防および治療用医薬の製造のための、ジクロロフェニル アミノベンゼン酢酸、メチルトルイル−ピロール酢酸、ヒドロキシメチル−ピリ ジルカルバモイル−ベンゾチアジンジオキシド、ジクロロメチルフェニルアミノ 安息香酸、メチル−メチルプロピルベンゼン酢酸、クロロベンゾイルメトキシ− メチルインドール酢酸およびフルオロメチル−メチルスルフィニル−フェニルメ チレン−インデン酢酸からなる群から選択される請求項9の組成物。 11.アテローム硬化性心臓血管疾患の予防および治療用組成物であって、アポ B/LDL分子の非酵素的グリコシル化に対して保護する治療上の分子および治 療上許容し得るキャリアーを含む組成物。 12.治療上の分子が、アテローム硬化性心臓血管疾患の予防および治療用医薬 の製造のための、ジクロロフェニルアミノベンゼン酢酸、メチルトルイル−ピロ ール酢酸、ヒドロキシメチル−ピリジルカルバモイル−ベンゾチアジンジオキシ ド、ジクロロメチルフェニルアミノ安息香酸、メチル−メチルプロピルベンゼン 酢酸、クロロベンゾイルメトキシ−メチルインドール酢酸およびフルオロメチル −メチルスルフィニル−フェニルメチレン−インデン酢酸からなる群から選択さ れる請求項11の組成物。 13.高コレステロール血症の予防および治療用組成物であって、アポB/LD L分子の非酵素的グリコシル化に対して保護する治療上の分子および治療上許容 し得るキャリアーを含む組成物。 14.治療上の分子が、アテローム硬化性心臓血管疾患の予防および治療用医薬 の製造のための、ジクロロフェニルアミノベンゼン酢酸、メチルトルイル−ピロ ール酢酸、ヒドロキシメチル−ピリジルカルバモイル−ベンゾチアジンジオキシ ド、ジクロロメチルフェニルアミノ安息香酸、メチル−メチルプロピルベンゼン 酢酸、クロロベンゾイルメトキシ−メチルインドール酢酸およびフルオロメチル −メチルスルフィニル−フェニルメチレン−インデン酢酸からなる群から選択さ れる請求項13の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60314796A | 1996-02-20 | 1996-02-20 | |
US08/603,147 | 1996-02-20 | ||
PCT/US1997/002622 WO1997029746A1 (en) | 1996-02-20 | 1997-02-19 | Inhibition of protein glycation and prevention of vasculopathy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002515031A true JP2002515031A (ja) | 2002-05-21 |
JP2002515031A5 JP2002515031A5 (ja) | 2004-11-04 |
Family
ID=24414273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52959097A Ceased JP2002515031A (ja) | 1996-02-20 | 1997-02-19 | タンパク質グリコシル化の阻害および血管疾患の予防 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0946170B8 (ja) |
JP (1) | JP2002515031A (ja) |
AT (1) | ATE306295T1 (ja) |
DE (1) | DE69734356T2 (ja) |
WO (1) | WO1997029746A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355680B1 (en) * | 1996-02-20 | 2002-03-12 | Exocell, Inc. | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
KR101166290B1 (ko) | 2009-08-24 | 2012-07-16 | 영남대학교 산학협력단 | 아포지단백질 α-i의 당화 억제제 스크리닝 방법 |
CN104840768A (zh) * | 2015-04-28 | 2015-08-19 | 王新花 | 一种治疗气阴两虚型肾小球源性血尿的中药制剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4060626A (en) * | 1972-01-26 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Indole-carboxylic carbon compounds and pharmaceutical compositions containing them |
US5245046A (en) * | 1988-11-14 | 1993-09-14 | The Upjohn Company | α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
-
1997
- 1997-02-19 AT AT97906922T patent/ATE306295T1/de not_active IP Right Cessation
- 1997-02-19 WO PCT/US1997/002622 patent/WO1997029746A1/en active IP Right Grant
- 1997-02-19 JP JP52959097A patent/JP2002515031A/ja not_active Ceased
- 1997-02-19 EP EP97906922A patent/EP0946170B8/en not_active Expired - Lifetime
- 1997-02-19 DE DE69734356T patent/DE69734356T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0946170A1 (en) | 1999-10-06 |
WO1997029746A1 (en) | 1997-08-21 |
EP0946170B8 (en) | 2005-12-07 |
EP0946170B1 (en) | 2005-10-12 |
ATE306295T1 (de) | 2005-10-15 |
DE69734356D1 (de) | 2006-02-23 |
DE69734356T2 (de) | 2006-07-06 |
EP0946170A4 (en) | 2002-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0666753B1 (en) | Use of peptides FOR THE TREATMENT OF THE COMPLICATIONS AND PATHOLOGY OF DIABETES | |
EP1572196B1 (en) | Combination of a dpp-iv inhibitor and a ppar-alpha compound | |
JP2001523663A (ja) | 進歩した糖化最終生成物中間体及び後−アマドリ阻害 | |
US20020091153A1 (en) | Novel anandamide amidase inhibitors as analgesic agents | |
JPS62201822A (ja) | 自己免疫性疾病の予防・治療剤 | |
JPH07503713A (ja) | 蛋白質の高度グリコシル化阻害剤として有用なアミノ酸 | |
CN1324234A (zh) | 果糖胺氧化酶,拮抗剂和抑制剂 | |
EA009528B1 (ru) | Пептид (варианты), содержащая его композиция и лекарственный препарат для профилактики и лечения атеросклероза | |
JPH08507516A (ja) | 脂質及び脂質含有粒子のグリコシル化、及びそれから誘導される診断及び治療方法及び物質 | |
EP1242069B1 (en) | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | |
JPH0597666A (ja) | 臨床的状態の治療に使用される両性イオン化合物およびそれらのn−ハロ誘導体 | |
JP2004525962A (ja) | 胆汁酸または胆汁酸塩脂肪酸結合体の使用 | |
US20040116350A1 (en) | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies | |
AU2002212970A1 (en) | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies | |
WO2002022573A2 (en) | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies | |
AU727895B2 (en) | Method for treating atherosclerosis with an MPT inhibitor and cholesterol lowering drugs | |
EP4149972A1 (en) | Combination therapy for ttr amyloidosis | |
JP2002515031A (ja) | タンパク質グリコシル化の阻害および血管疾患の予防 | |
AU2008253667A1 (en) | Treatment of allergic disease with immunomodulator compounds | |
EP1341532B1 (en) | Use of pyridoxamine for the treatment and inhibition of obesity-related complications | |
CA2246657C (en) | Inhibition of protein glycation and prevention of vasculopathy | |
US5994401A (en) | In Vivo Methods to reduce hypercholesterolemia and improve vascular dysfunction | |
JP3035343B2 (ja) | 腸内鉄吸収性を制御するための経口投与ポルフィリン類 | |
US6001875A (en) | In vivo methods of treatment to prevent kidney dysfunction using substances that inhibit albumin glycation | |
US20240226069A1 (en) | Vafidemstat for use in treating autism spectrum disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031208 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070731 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071219 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080212 |